Want to see IN:LASA full AI Analyst Report?
Top Page
Lasa Supergenerics Ltd.
(LASA)
Select Model
Select Model
Rating:42Neutral
Price Target:
₹6.50
▼(-4.69% Downside)
Action:Reiterated
Date:09/06/26
The score is held down primarily by weak financial performance (sharp revenue decline, deeply negative margins, and renewed negative operating cash flow). Technical indicators add further pressure, with price trading below key moving averages and negative MACD. Valuation provides limited support because the company is loss-making (negative P/E) and no dividend yield is available.
Positive Factors
Manageable Leverage
Relatively low leverage gives LASA more balance-sheet flexibility than a heavily indebted business and may reduce refinancing pressure. This provides some capacity to absorb operating volatility or support recovery efforts, although persistent losses could gradually weaken that flexibility.
Negative Factors
Severe Revenue Contraction
The sharp FY2026 revenue decline, following an earlier downward trend, indicates substantial deterioration in commercial activity rather than a brief fluctuation. Persistently weaker sales can reduce plant utilization, spread fixed costs over fewer units, and make a durable earnings recovery more difficult.
Read all positive and negative factors
Positive Factors
Negative Factors
Manageable Leverage
Relatively low leverage gives LASA more balance-sheet flexibility than a heavily indebted business and may reduce refinancing pressure. This provides some capacity to absorb operating volatility or support recovery efforts, although persistent losses could gradually weaken that flexibility.
Read all positive factors
Lasa Supergenerics Ltd. (LASA) vs. iShares MSCI India ETF (INDA)
Market Cap
₹330.17M
Dividend Yield0.67%
Average Volume (3M)6.13K
Price to Earnings (P/E)―
Beta (1Y)1.26
Revenue Growth-95.17%
EPS Growth50.09%
CountryIN
Employees77
SectorGeneral
Sector StrengthN/A
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)-3.30
Shares Outstanding50,101,240
10 Day Avg. Volume4,642
30 Day Avg. Volume6,132
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.57
Price to Sales (P/S)1.13
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Lasa Supergenerics Ltd. Business Overview & Revenue Model
Company Description
Lasa Supergenerics Limited, founded in 2016 and based in Mumbai, India, specializes in the development, manufacturing, and commercialization of various healthcare products for both human and animal well-being. Its operations predominantly cater to...
How the Company Makes Money
LASA primarily makes money by manufacturing and selling pharmaceutical APIs and intermediates to other pharmaceutical companies (e.g., generic drug manufacturers and formulators) that use these inputs to produce finished medicines. Revenue is gene...
Lasa Supergenerics Ltd. Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
58
Neutral
Cash Flow
27
Negative
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 63.56M | 251.41M | 1.42B | 1.04B | 1.30B | 1.37B |
| Gross Profit | -84.79M | -68.91M | 362.61M | 286.95M | -111.88M | 427.84M |
| EBITDA | -82.48M | -282.04M | -43.91M | -64.66M | -246.85M | 84.12M |
| Net Income | -165.50M | -340.90M | -147.57M | -217.31M | -386.21M | -53.31M |
Balance Sheet | ||||||
| Total Assets | 0.00 | 665.67M | 1.02B | 1.51B | 1.64B | 2.09B |
| Cash, Cash Equivalents and Short-Term Investments | 6.97M | 6.97M | 7.90M | 14.96M | 21.78M | 172.17M |
| Total Debt | 0.00 | 97.47M | 21.27M | 220.76M | 217.70M | 201.71M |
| Total Liabilities | -496.23M | 169.44M | 178.19M | 541.92M | 455.69M | 512.87M |
| Stockholders Equity | 496.23M | 496.23M | 837.13M | 966.76M | 1.18B | 1.58B |
Cash Flow | ||||||
| Free Cash Flow | -899.00K | 0.00 | -28.24M | 21.39M | -173.00M | 92.12M |
| Operating Cash Flow | 2.59M | -80.67M | -28.24M | 21.39M | -173.00M | 92.12M |
| Investing Cash Flow | -1.00M | 3.27M | 81.52M | -3.98M | 111.95M | -29.12M |
| Financing Cash Flow | -1.46M | 77.53M | -56.62M | -19.32M | -41.61M | -403.00K |
Lasa Supergenerics Ltd. Technical Analysis
Negative
6.82
Price Trends
7.19
Negative
7.53
Negative
8.15
Negative
Market Momentum
-0.17
Positive
37.06
Neutral
28.53
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:LASA, the sentiment is Negative. The current price of 6.82 is below the 20-day moving average (MA) of 7.04, below the 50-day MA of 7.19, and below the 200-day MA of 8.15, indicating a bearish trend. The MACD of -0.17 indicates Positive momentum. The RSI at 37.06 is Neutral, neither overbought nor oversold. The STOCH value of 28.53 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:LASA.
Lasa Supergenerics Ltd. Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
81 Outperform | ₹1.74B | 11.96 | ― | 0.70% | 4.29% | 2.40% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
49 Neutral | ₹1.69B | 23.66 | ― | 1.12% | 13.51% | -14.80% | |
49 Neutral | ₹551.30M | -1.51 | ― | 0.28% | -22.27% | -291.72% | |
47 Neutral | ₹599.36M | 116.33 | ― | ― | 9.31% | -82.71% | |
45 Neutral | ₹513.24M | -0.28 | ― | 0.67% | -39.80% | -452.04% | |
42 Neutral | ₹330.17M | -1.98 | ― | 0.67% | -95.17% | 50.09% |
* General Sector Average
IN:LASA
Lasa Supergenerics Ltd.
6.59
-5.09
-43.58%
IN:BALPHARMA
Bal Pharma Limited
107.47
18.66
21.01%
IN:BIOFILCHEM
Biofil Chemicals & Pharmaceuticals Ltd.
34.48
-9.59
-21.76%
IN:MANGALAM
Mangalam Drugs & Organics Ltd.
36.37
-38.96
-51.72%
IN:PAR
Par Drugs and Chemicals Limited
140.92
32.28
29.71%
IN:VIVIMEDLAB
Vivimed Labs Limited
6.07
1.17
23.88%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.